Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or metastatic non small cell lung cancer~* Undertaken EGFR TKIs treatment (gefitinib, erlotinib, icotinib, afatinib, etc)~  * 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance score 0-2~* Moderate or severe pruritus (VAS score ≥ 4) first occur after EGFR TKIs treatment~* Life expectancy ≥ 3 months~* Orally drug administration with no difficulty~* pregnancy test negative in 7 days for women of child-bearing age; willing to take contraception measures.~* Signed informed consent form (ICF)~Exclusion Criteria:~* Systemically treatment with Neurokinin-1 (NK-1) receptor inhibitors, antihistamines drugs, antibiotics, cortical hormone therapy, antiepileptic drugs, immunosuppressive agents or other drugs might affect treatment in 4 weeks; or locally used of these drug in 2 weeks.~* Existing skin lesions not EGFR TKIs related, such as skin infection, chronic dermatitis, Systemic Lupus Erythematosus (SLE), lymphoma or other diseases.~* Total bilirubin ≥ 1.5 Upper Limit Of Normal (ULN)~* Serum creatinine ≥mg/dl~* AST or ALT ≥ 2.5 ULN without liver metastasis; or ≥ 5 ULN with liver metastasis.~* Residual toxicity event ≥ CTC-AE grade 2, except peripheral neurotoxicities.~* Central nervous system (CNS) metastasis or spinal compression; except no symptoms and with no cortical hormonotherapy in 4 weeks.~* Clinical evidence of interstitial lung disease~* Any severe or uncontrolled systemic diseases judged by investigators.~* Any contraindication of Neurokinin-1 receptor inhibitors and desloratadine.~Discontinuation Criteria~* Invalid subject after randomization~* Major protocol violations judged by investigators.~* Poor compliance~* Intolerable adverse events~* Subject withdraw ICF~* Any pregnancy events~* No clinical benefits due to clinical adverse events, laboratory abnormalities or other medical conditions~* Other reasons of treatment discontinuation judged by investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant and placebo (Type: EXPERIMENTAL): aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
- desloratadine and placebo (Type: ACTIVE_COMPARATOR): placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28

Based on this trial design, predict the completion outcome and termination type (if applicable).